Pregabalin Augmentation of Quetiapine Therapy in the Treatment of Fibromyalgia: An Open-Label, Prospective Trial

Abstract

Introduction: Quetiapine has been shown to improve fibromyalgia symptoms, especially sleep disturbance, fatigue, morning stiffness, and mental well-being, but lacks an effect on pain. The purpose of this study was to evaluate if pregabalin, which has shown antialgic activity in fibromyalgia, added to quetiapine treatment additionally improved fibromyalgia symptomatology.

Methods: This was an open-label, 12-week study. Pregabalin was administered to 19 female fibromyalgia patients at a starting dose of 75 mg/day subsequently adjusted in according to the drug's efficacy and tolerability. Outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), the Pittsburgh Sleep Quality Index, the Beck Depression Inventory, the State and Trait Anxiety Inventory, and the SF-12 Health Survey.

Results: Data analysis was done on the Intention-To-Treat sample which included 18 patients. Pregabalin significantly improved the pain and tiredness after awakening subscales of the FIQ as well as the physical component of the SF-12. Six patients withdrew from the study, 3 because of side effects.

Conclusions: Our results suggest that the use of pregabalin can be a useful augmentation strategy in fibromyalgia patients partially responding to quetiapine.

fibromyalgia - pain - quetiapine - pregabalin

References

• 1 Aaron LA, Buchwald D. Chronic diffuse muskuloskeletal pain, fibromyalgia and comorbid unexplained medical conditions.  Best Pract Res Clin Rheumatol. 2003;  17 563-574
• 2 Arnold LM. Biology and therapy of fibromyalgia. New therapies in fibromyalgia.  Arthritis Res Ther. 2006;  8 212 DOI: doi:10.1186/ar1971 , (Epub ahead of print)
• 3 Ben Menachem E. Pregabalin pharmacology and its relevance to clinical practice.  Epilepsia. 2004;  45 13-18
• 4 Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia: a double-blind, randomized, placebo-controlled study.  Am J Med. 2003;  114 537-545
• 5 Crofford LJ. Pharmaceutical treatment options for fibromyalgia.  Curr Rheumatol Rep. 2004;  6 274-280
• 6 Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE. et al . Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 2005;  52 1264-1273
• 7 Feltner DE, Crockatt JC, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD. et al . A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.  J Clin Psychopharmacol. 2003;  23 240-249
• 8 Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Do the second generation “atypical neuroleptics” have analgesic properties? A structured evidence-base review.  Pain Med. 2005;  5 359-365
• 9 Fossaluza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome.  Int J Clin Pharm Res. 1992;  12 99-102
• 10 Golbenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia.  Arthritis Rheum. 1996;  39 1852-1859
• 11 Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome.  JAMA. 2004;  292 2388-2395
• 12 Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia.  Prog Neuropsychopharmacol Biol Psychiatry. 2007;  31 71-77
• 13 Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramiprexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.  Arthritis Rheum. 2005;  52 2495-2505
• 14 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiatry. 2006;  39 47-51
• 15 Kavoussi R. Pregabalin: from molecule to medicine.  Eur Neuropsycho-pharmacol. 2006;  16 128-133
• 16 Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status.  Med Care. 1989;  27 178-189
• 17 Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.  J Rheumatol. 2005;  32 6-21
• 18 Pande AC, Crockatt JC, Feltner DE, Janney CA, Smith WT, Weisler R. et al . Pregabalin in generalized anxiety disorder: a placebo-controlled trial.  Am J Psychiatry. 2003;  160 533-540
• 19 Samborski W, Lezanska-Szpera M, Rybakowsky JK. Open trial of mirtazapine in patients with fibromyalgia.  Pharmacopsychiatry. 2004;  37 168-170

Correspondence